Added to YB: 2026-05-28
Pitch date: 2026-05-25
ACL.AX [neutral]
Australian Clinical Labs Limited
Author Info
No bio for this author
Company Info
Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers range of services, including molecular cancer, harmony NIPT, genetic carrier screening and other antenatal, cardiac, and commercial drug and alcohol testing services; chemical pathology, haematology, histopathology and cytopathology, serology and microbiology, allergy and immunology, and veterinary and functional pathology services; pathology services for clinical trials; and CPD programs.
Market Cap
AUD 376.6M
Pitch Price
N/A
Price Target
N/A
Dividend
6.19%
EV/EBITDA
3.29
P/E
14.33
EV/Sales
0.91
Sector
Health Care Providers and Services
Category
value
Australian Clinical Labs: Why I see an opportunity in Australia's pathology service provider
ACL.AX (watchlist): Australia pathology provider at 11x NTM P/E vs 21x market, consensus pricing no growth despite MSD revenue potential. Jul'25 MBS indexation adds ~0.8ppt growth; industry grew 5% p.a. since FY2017 on 3% volume + mix shift; aging 65+ population (+2.9% CAGR to FY2030). H1'26 rev -1% YoY from exiting unprofitable contracts, but EBIT margin improved 7.4%→7.7%. 8% ROA vs HLS losses despite half the size. GP attendance weak but Nov'25 bulk billing expansion should drive recovery post-FY2026. Sustainable capital returns ~10% of market cap (5% premium to Aus 10y). KKR lifted stake to 8.2% (from 7.2%), potential PE takeover catalyst. CEO departure Aug'26 adds uncertainty.
Read full article (6 min)